ReN 009

Drug Profile

ReN 009

Alternative Names: CTX cells; CTX DP; CTX-0E03 - ReNeuron - ReN009; ReN-009

Latest Information Update: 29 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ReNeuron
  • Class Anti-ischaemics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Peripheral ischaemia

Most Recent Events

  • 29 Mar 2016 Phase I development is ongoing in the UK
  • 03 Apr 2014 Phase-I clinical trials in Peripheral ischaemia (specifically lower limb ischaemia in the elderly) in United Kingdom (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top